• Explore /
  • Poster
  • / Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3‑activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.

Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3‑activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.

Abstract Poster

Authors

Apostolia Tsimberidou

Apostolia Maria Tsimberidou

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Apostolia Maria Tsimberidou , Claire F. Verschraegen , Pei Hsu , Tillman E. Pearce

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT03592264

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3030)

DOI

10.1200/JCO.2022.40.16_suppl.3030

Abstract #

3030

Poster Bd #

22

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Miguel Angel Villalona-Calero

First Author: Ursula A. Matulonis

First Author: Philippe L. Bedard